Moderna in den Nachrichten
mRNA-basierte Medikamentenentwicklung
Tamtam hat 20 aktuelle Artikel über Moderna gefunden.
- Moderna’s Surprise Rally Defies Bears Amid New Vaccine Hopes
- Moderna’s Cancer Vaccine Win Fuels Broad Push Across Tumor Types
- The Melanoma Win Is Real, The Price Isn't - Moderna And MRNY Both Sell (NASDAQ:MRNA)
- Moderna (MRNA) Ascends While Market Falls: Some Facts to Note
- What Analysts Are Saying About Moderna Stock
- Moderna downgraded to neutral at UBS on questions over revenue growth
- Moderna just had its best day since October. Here's what's going on, and what analysts expect
- BofA Adjusts Price Target on Moderna to $24 From $21, Maintains Underperform Rating
- Why Moderna Shares Are Quietly Climbing Off the Lows
- Moderna stock price target raised to $24 from $21 at BofA Securities
- Moderna (MRNA): Reassessing Valuation After a Modest Share Price Rebound
- Moderna reaffirms 2025-26 guidance, eyes multiple vaccine, oncology, and rare disease launches
- Moderna issues shareholder letter under Regulation FD disclosure
- Moderna, Inc. Reports 2025 Achievements and 2026 Outlook
- Moderna, searching for a rebound, to seek approval of mRNA flu shot
- Moderna Submits Application for mRNA-Based Seasonal Flu Vaccine Approval
- Moderna seeks flu vaccine approvals; Neumora Alzheimer’s data
- Moderna Announces Global Regulatory Submissions for Its Investigational Seasonal Influenza Vaccine
- Moderna Announces Global Regulatory Submissions for Its Investigational Seasonal Influenza Vaccine
- Why Is Moderna (MRNA) Stock Rocketing Higher Today
Von Tamtam gesammelte Artikel, die sich auf das Unternehmen beziehen, die neuesten zuerst. Jeder verlinkt auf seine Quelle.
Sie verkaufen an Unternehmen wie Moderna?
Tamtam findet die Unternehmen, die zu Ihrem idealen Kunden passen, recherchiert jeden Account und sagt Ihnen, wen Sie wann kontaktieren sollten.
Ähnliche Unternehmen finden